These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38279671)

  • 41. Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?
    Anderson VM; McIlwain ME; Kydd RR; Russell BR
    Psychiatry Res; 2015 Dec; 230(3):811-8. PubMed ID: 26564550
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia.
    Bogers JPAM; Schulte PFJ; Broekman TG; de Haan L
    J Clin Psychopharmacol; 2023 Mar-Apr 01; 43(2):97-105. PubMed ID: 36825865
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacometabolomics-guided clozapine therapy in treatment resistant schizophrenia: Preliminary exploration of future too near.
    Grover S; Kasudhan KS; Murali N; Patil AN; Pattanaik S; Chakrabarti S; Avasthi A
    Asian J Psychiatr; 2022 Jan; 67():102939. PubMed ID: 34844176
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship between clinical improvement and functional gains with clozapine in schizophrenia.
    Lee J; Takeuchi H; Fervaha G; Bhaloo A; Powell V; Remington G
    Eur Neuropsychopharmacol; 2014 Oct; 24(10):1622-9. PubMed ID: 25156578
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of Smoking Status on Remission and Metabolic and Cognitive Outcomes in Schizophrenia Patients Treated with Clozapine.
    Wagner E; Oviedo-Salcedo T; Pelzer N; Strube W; Maurus I; Gutwinski S; Schreiter S; Kleymann P; Morgenroth CL; Okhuijsen-Pfeifer C; Luykx JJ; Falkai P; Schneider-Axmann T; Hasan A
    Pharmacopsychiatry; 2020 Nov; 53(6):273-283. PubMed ID: 32757178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study.
    Ochi S; Tagata H; Hasegawa N; Yasui-Furukori N; Iga JI; Kashiwagi H; Kodaka F; Komatsu H; Tsuboi T; Tokutani A; Numata S; Ichihashi K; Onitsuka T; Muraoka H; Iida H; Ohi K; Atake K; Kishimoto T; Hori H; Takaesu Y; Takeshima M; Usami M; Makinodan M; Hashimoto N; Fujimoto M; Furihata R; Nagasawa T; Yamada H; Matsumoto J; Miura K; Kido M; Hishimoto A; Ueno SI; Watanabe K; Inada K; Hashimoto R
    Int J Neuropsychopharmacol; 2022 Oct; 25(10):818-826. PubMed ID: 35723038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.
    Sharma T; Hughes C; Soni W; Kumari V
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):398-403. PubMed ID: 12845415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.
    Suzuki T; Remington G; Arenovich T; Uchida H; Agid O; Graff-Guerrero A; Mamo DC
    Br J Psychiatry; 2011 Oct; 199(4):275-80. PubMed ID: 22187729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
    Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
    Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment.
    Vayısoğlu S; Anıl Yağcıoğlu AE; Yağcıoğlu S; Karahan S; Karcı O; Gürel SC; Yazıcı MK
    Schizophr Res; 2013 Jan; 143(1):207-14. PubMed ID: 23217729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics.
    Han M; Zhang XY; Chen DC; Tan YL; Song CS; Yu YH; Huang XF
    Int Clin Psychopharmacol; 2015 Mar; 30(2):89-95. PubMed ID: 25568968
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients.
    Molins C; Carceller-Sindreu M; Navarro H; Carmona C; Piñeiro M; Martínez E; Álvarez E; Portella MJ
    Psychiatry Res; 2017 Dec; 258():153-157. PubMed ID: 29024893
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.
    Krakowski M; Czobor P
    Schizophr Res; 2011 Aug; 130(1-3):27-33. PubMed ID: 21549568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine.
    Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
    Psychiatry Res; 1997 Mar; 69(2-3):113-21. PubMed ID: 9109179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Electroconvulsive therapy for treatment-resistant schizophrenia.
    Sinclair DJ; Zhao S; Qi F; Nyakyoma K; Kwong JS; Adams CE
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD011847. PubMed ID: 30888709
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.
    Shiloh R; Zemishlany Z; Aizenberg D; Radwan M; Schwartz B; Dorfman-Etrog P; Modai I; Khaikin M; Weizman A
    Br J Psychiatry; 1997 Dec; 171():569-73. PubMed ID: 9519099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms.
    Lee J; Takeuchi H; Fervaha G; Sin GL; Foussias G; Agid O; Farooq S; Remington G
    Can J Psychiatry; 2015 Nov; 60(11):515-22. PubMed ID: 26720509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.
    Dossenbach MRK ; Beuzen JN; Avnon M; Belmaker RH; Elizur A; Mark M; Munitz H; Schneidman M; Shoshani D; Kratky P; Grundy SL; Tollefson GD
    Clin Ther; 2000 Sep; 22(9):1021-34. PubMed ID: 11048902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.
    Nakajima S; Takeuchi H; Fervaha G; Plitman E; Chung JK; Caravaggio F; Iwata Y; Mihashi Y; Gerretsen P; Remington G; Mulsant B; Graff-Guerrero A
    Schizophr Res; 2015 Feb; 161(2-3):429-33. PubMed ID: 25556080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment.
    Faden J; Citrome L
    Expert Opin Pharmacother; 2019 Jan; 20(1):11-24. PubMed ID: 30407873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.